Investigation Effect of Glimepiride on Diabetic Marker and Cardiac Lipid Parameter in Isoproterenol Induced Myocardial Infarction in Diabetes in Rats

Present study was designed to evaluate effect Glimepiride on Glucose, HbA1c, lipid profile and Lipid Metabolizing Enzymes in isoproterenol induced myocardial infarction in normal and Streptozotocin-Nicotinamide induced in diabetic rats. Glimepiride (0.5 mg/kg, p.o) was administered for 28 days in rats injected with single dose of Streptozotocin (65 mg/kg, i.p, STZ) and Nicotinamide (110 mg/kg, i.p, NIC) and after isoproterenol (200 mg/kg, s.c.) induced myocardial infarction in rats on 29th and 30th day. At the end of experimental period (i.e. on the day 31) serum and heart tissues sample were collected, and glucose, HbA1c and Total Cholesterol (TC), Triglycerides (TG) and High density lipoprotein (HDL) and cholesterol ester synthetase (CES), lecithin Cholesterol acyl transferase (LCAT), lipoprotein lipase (LPL) were find out.Administration of STZ–NIC in rats showed a significant (p<0.001) increased in the levels of serum glucose, glycosylated heamoglobin (HbA1c), Total Cholesterol (TC), Triglycerides (TG) and Low density lipoprotein (LDL) whereas the levels of High density lipoprotein (HDL) were found to be non significant but significant (p<0.001) increased in the level of heart tissues CES and significant (p<0.001, p<0.01) decreased LCAT and LPL as compared to respective control groups. Treatment with Glimepiride significantly (P<0.001) decreased HbA1c, glucose, CES level and significantly (P<0.001, P<0.05, P<0.05) decreased LDL, TC and TG and significant (P<0.01) increased LCAT and LPL level but no significantly change HDL in compared to diabetic control group.This study suggested that GLI (0.5 mg/kg) is effective in controlling blood glucose levels and improves lipid profile and lipid metabolizing enzymes in experimentally induced myocardial infarction diabetic rats. Keywords: Glimepiride, Glucose, HbA1c, lipid profile, lipid metabolic enzymes